Egr-2 and Egr-3 are negative regulators of T cell activation-Reference-Cited by-同舟云学术

Egr-2 and Egr-3 are negative regulators of T cell activation

Published:2005-04-17 Issue:5 Volume:6 Page:472-480
ISSN:1529-2908
Container-title:Nature Immunology
language:en
Short-container-title:Nat Immunol

Author:

Safford Meredith,Collins Samuel,Lutz Michael A,Allen Amy,Huang Ching-Tai,Kowalski Jeanne,Blackford Amanda,Horton Maureen R,Drake Charles,Schwartz Ronald H,Powell Jonathan D

Publisher

Springer Science and Business Media LLC

Subject

Immunology,Immunology and Allergy

Link

http://www.nature.com/articles/ni1193.pdf

Reference32 articles.

1. Schwartz, R.H. Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell 71, 1065–1068 (1992).

2. Medzhitov, R. & Janeway, C.A., Jr. How does the immune system distinguish self from nonself? Semmin. Immunol. 12, 185–188 (2000).

3. Diehn, M. et al. Genomic expression programs and the integration of the CD28 costimulatory signal in T cell activation. Proc. Natl. Acad. Sci. USA 99, 11796–11801 (2002).

4. Riley, J.L. et al. Modulation of TCR-induced transcriptional profiles by ligation of CD28, ICOS, and CTLA-4 receptors. Proc. Natl. Acad. Sci. USA 99, 11790–11795 (2002).

5. Macian, F. et al. Transcriptional mechanisms underlying lymphocyte tolerance. Cell 109, 719–731 (2002).

Cited by 362 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Aging and viral evolution impair immunity against dominant pan-coronavirus-reactive T cell epitope;2024-08-21

2. Establishing an evaluation system for T cell activation and anergy based on CD25 expression levels as an indicator;Cytotechnology;2024-08-19

3. Dynamic chromatin architecture identifies new autoimmune-associated enhancers for IL2 and novel genes regulating CD4+ T cell activation;2024-08-15

4. Dynamic chromatin architecture identifies new autoimmune-associated enhancers for IL2 and novel genes regulating CD4+ T cell activation;2024-08-15

5. Effector T cells in poorly perfused tumor regions exhibit a distinct signature of augmented IFN response and reduced PD-1 expression;2024-07-08